<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13077">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02936674</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-10165</org_study_id>
    <nct_id>NCT02936674</nct_id>
  </id_info>
  <brief_title>Color-dependent Melatonin Suppression</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Palo Alto Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Palo Alto Health Care System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of complex, broad-band spectra light on
      the production of melatonin in humans.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Melatonin suppression</measure>
    <time_frame>4 Hours</time_frame>
    <description>The amount of declination of salivary melatonin concentrations between the start of the light and the end of the light (4 hours later) will be compared between the conditions.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Melatonin</condition>
  <arm_group>
    <arm_group_label>Light 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Light 1 will have an altered color composition as compared with a standard LED bulb.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Light 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Light 2 will be a standard LED bulb.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Light - standard</intervention_name>
    <description>Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with standard spectral distribution</description>
    <arm_group_label>Light 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Light - alternate</intervention_name>
    <description>Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with an altered spectral distribution (different color)</description>
    <arm_group_label>Light 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable health

          -  Normal color vision

          -  Normal hearing

          -  18-35 years old

        Exclusion Criteria:

          -  Significant depressive symptoms

          -  Pregnant or nursing

          -  Ocular pathologies

          -  Unstable or severe medical or psychiatric condition

          -  Extreme morning/evening type

          -  Regular smoker

          -  Use of medications that impact ocular function

          -  Alcohol use disorder

          -  Use of illegal drugs

          -  Irregular use of antihistamines, antidepressants, or sleeping medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ann Wang</last_name>
    <phone>650-493-5000</phone>
    <email>cheng.ann.wang@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Wang</last_name>
      <phone>650-493-5000</phone>
      <email>cheng.ann.wang@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 17, 2016</lastchanged_date>
  <firstreceived_date>October 7, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VA Palo Alto Health Care System</investigator_affiliation>
    <investigator_full_name>Jamie M. Zeitzer, Ph.D.</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All relevant individual data will be published.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
